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Abstract
Mitral regurgitation (MR) is the second most common form of valvular disease requiring 
surgery. Correct identification of surgical candidates and optimising the timing of surgery are 
key in management. For primary MR, this relies upon a balance between the peri-operative 
risks and rates of successful repair in patients undergoing early surgery when asymptomatic 
with the potential risk of irreversible left ventricular dysfunction if intervention is performed 
too late. For secondary MR, recognition that this is a highly dynamic condition where MR 
severity may change is key, although data on outcomes in determining whether concomitant 
valve intervention is performed with revascularisation has raised questions regarding 
timing of surgery. There has been substantial interest in the use of stress echocardiography 
to risk stratify patients in mitral regurgitation. This article reviews the role of stress 
echocardiography in both primary and secondary mitral regurgitation and discusses how this 
can help clinicians tackle the challenges of this prevalent condition.
Introduction
Mitral regurgitation (MR) is the second most common type 
of valve disease requiring surgery in Europe (1). Despite a 
reduction in the incidence of rheumatic heart disease, the 
frequency of MR is increasing due to an ageing population 
(2). Improvements in the diagnosis, quantification and 
operative techniques for mitral valve (MV) repair now allow 
the restoration of normal life expectancy after surgery (3). 
The timing and type of surgery depend upon a number of 
factors, one of the most important being whether the MR is 
primary or secondary (Videos 1 and 2). The balance in each 
case then lies between facing the risks of early surgery and 
risking left ventricular (LV) dysfunction if intervention is 
performed too late. In addition, consideration has to be given 
to the risk of mitral valve replacement in case of immediate 
failure of repair and the risk of re-intervention in the 
situation of late failure of repair. Unfortunately, a significant 
proportion of those with severe MR who have apparently 
normal LV function pre-operatively (LVEF >60%) continue 
to present post-operatively with reduced ejection fraction 
and congestive cardiac failure (4). This article outlines the 
discussion surrounding the timing of surgery and highlights 
the importance of exercise stress echocardiography in the 
management of primary and secondary MR.
Video 1
Primary mitral regurgitation with flail A2 scallop of 
the anterior mitral valve leaflet. View Video 1 at 
http://movie-usa.glencoesoftware.com/video/10.1530/
ERP-16-0019/video-1.
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Video 2
Secondary ischaemic mitral regurgitation (asymmetric). 
View Video 2 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-16-0019/video-2.
Controversy in the timing of surgery for 
primary MR
Class 1 indications for surgery in primary MR have been 
unchanged for many years (5). In recent years, this 
‘conventional’ approach has been challenged by advocates 
for early MV repair who have come to regard standard class I 
triggers such as heart failure and LV dysfunction as promoting 
‘rescue surgery’ (6). Data to support this view originated in 
operative series from the 1980s, which highlighted improved 
surgical outcomes in patients operated with NYHA class I–II 
rather than NYHA III–IV symptoms (3). In the modern era, 
several observational series have consistently demonstrated 
adverse outcomes for each of the individual components 
of the current class I surgical indications. In a prospective 
surgical series of 840 patients with MR amenable to repair, 
worsening NYHA classification was associated with a 
stepwise reduction in late survival rates 20  years after 
surgery (7). In a retrospective case registry, mortality was 
increased by 80% at 10-year follow-up once EF had fallen 
to 50–59% compared with those in whom LVEF remained 
above 60% (8). Furthermore, LV dilatation above 40 mm in 
end-systole in primary MR predicted excess mortality and 
was an independent predictor of permanent post op LV 
dysfunction (9). Summarising the risks of delay to repair, a 
retrospective of 1512 patients undergoing isolated primary 
MR at the Rochester Mayo clinic between 1990 and 2000 
found long-term survival at 15 years was only 42 ± 2% for 
patients with a class I indication, compared with 53 ± 4% 
for those with a class II surgical indication including 
presence of atrial fibrillation or pulmonary hypertension, 
with the highest survival (70 ± 3%) observed in subjects 
receiving early operation based on the presence of a high 
probability of successful repair. Furthermore, operative 
mortality was only documented in those with a class I 
indication for surgery (6). These data have led authors to 
suggest that current class 1 recommendations are criteria 
that do not promote optimal outcomes for patients with 
severe primary MR.
Outcomes of mitral repair in primary MR
Registry studies have established that the results of MV 
repair are superior to replacement, even in the elderly (10). 
Prosthetic valve replacement is associated with higher 
operative mortality, reduced life expectancy, higher long-
term risk of stroke and complications specific to valve 
replacement such as valve thrombosis and structural valve 
degeneration (11). If repair can be successfully performed 
before the onset of advanced symptoms, data from expert 
centres report equivalent long-term outcomes to age- and 
gender-matched controls at >20-year follow-up (7). Both 
prospective and registry data support early repair before 
class 1 indications are reached. A single-centre prospective 
study of 610 consecutive patients with asymptomatic 
severe MR diagnosed with quantitative echocardiography 
compared outcomes between those referred for early 
surgery (235 patients; 94% repair rate) and those referred 
with conventional class 1 indications (375 patients; 82% 
repair rate), with the decision made at the discretion of 
the referrer. At a follow-up of 12 years, the early surgery 
group had significantly lower cardiac mortality (HR 0.109; 
95% confidence interval (CI) 0.014–0.836; P = 0.033) 
and cardiac event rates (HR 0.216; 95% CI 0.083–0.558; 
P = 0.002) (12). The multi-centre, multi-national Mitral 
Regurgitation International Database included 2097 
consecutive patients with primary MR due to flail 
segments and found improved survival at 10 years with 
lower rates of heart failure for those proceeding with early 
mitral repair compared with those managed medically 
until class 1 guidelines were triggered (13).
Mitral repair as a class 2A indication  
for surgery
Given the consistency of these data, why do current 
guidelines (5) not emphasise the importance of earlier 
repair for all patients with severe, degenerative MR? 
First, the data supporting early surgery are mostly from 
single-centre, non-randomised studies and many findings 
are from retrospective registries. These have tended to 
be high-volume centres with specialised, experienced 
surgeons performing large numbers of MV repairs. Such 
data on rates of repair and lower perioperative morbidity 
and mortality cannot always be extrapolated to lower-
volume centres (14, 15). Randomised prospective studies 
in mixed populations are lacking; however, trials are 
under way (16). Secondly, the benefits of such long-term 
outcomes are mainly reserved for those with primary 
degenerative disease (Carpentier mechanism type II) and 
outcomes are less consistent for other causes, including 
rheumatic disease (17). Thirdly, it can be more difficult 
to persuade an asymptomatic patient in clinic to 
undergo major cardiothoracic surgery – by definition, 
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prophylactic surgery in asymptomatic individuals does 
not improve how they feel (although this is not an issue 
in conditions when mortality benefit is clear, for example 
aortic aneurysm surgery). Finally, there are also data that 
suggest careful outpatient care may deliver outcomes that 
are as good. In a study of 132 consecutive patients with 
asymptomatic severe MR, a programme of annual review 
with referral based on class 1 indications also delivered 
outcomes equivalent to the general population over a 
follow-up period of 62 ± 26 months – but with the added 
advantage that 55 ± 6% of the population were able to 
avoid surgery completely at 8-year follow-up without 
complication (18). Of equal importance was that surgical 
outcomes were also excellent, with no compromise in 
symptomatic status or LV outcome from delay.
Moreover, referral for early surgery may often not 
be a straightforward decision – even with quantitative 
echocardiography, grading severe MR is subject to 
significant variation between operators (19). When 
severe MR is confirmed, the ability to identify a reparable 
MV is not perfect. Although in the US there has been a 
significant improvement in rate of repair with promotion 
of the ‘mitral valve surgeon’ and discouragement of lower 
volume centres so that repair is performed in excess of 
90% cases (20), this is not universal across all surgeons and 
in all countries. In the randomised prospective study of 
Kang and coworkers, recruiting only those with presumed 
reparable valves, repair was actually carried out in 94% 
(12). In the UK, audit data from the National Institute for 
Cardiovascular Outcomes Research (NICOR) identified 
that 1558 isolated first-time MV repairs were carried out 
in 2013, compared with 789 isolated MV replacements. 
The 1-year and 5-year mortality rates for isolated MV 
repair in 2013 were 1.1% and 11% respectively, but 
double for MV replacement at 2.4% and 20% (21). Such 
diverse surgical practice is of major concern, especially 
when considering the higher mortality and morbidity 
with MV replacement compared with MV repair and has 
prompted a call for defined centres of excellence for mitral 
valve repair in the UK with the presence of a dedicated 
heart valve team (22). Finally, MV repair is not risk free. 
In the UK, NICOR data reported mortality in 2013 for 
the first time, isolated MV repair at 1.09% and 2.79% 
when combined with coronary artery bypass grafting 
(CABG) (21). Furthermore, although actual survival far 
exceeds expected outcomes (5.19%), MR can still recur 
after repair. In the most recent series, rates of recurrent 
MR were 13.3 + 1.2% patients at 15-year follow-up, with 
a reoperation rate of 6.9 + 1.0% (23). Although serial data 
from this study suggest that rates of late failure are falling, 
possibly as a result of technical improvements such as 
routine use of ring annuloplasty and peri-operative 3D 
transoesophageal echocardiography, recurrence of MR 
after MV repair is associated with adverse LV remodelling 
and increased risk of death (23). For an asymptomatic 
patient to run this risk, there has to be certainty for that 
person that his or her own operative risk is low, that valve 
repair will be durable and that their own life expectancy 
will be long enough to benefit in the long term from any 
prognostic gain.
Stress echocardiography: improving risk 
stratification in primary MR
In addition to markers of adverse outcome that 
include the onset of atrial fibrillation (24), pulmonary 
hypertension (6) and left atrial dilatation (25), objective 
testing of symptom status is a critical step in decision 
making. Studies in those with severe aortic stenosis have 
emphasised that patients often minimise their symptoms 
by avoiding exercise and that objective testing may reveal 
limitations unsuspected on history alone. Similarly, in 
severe ‘asymptomatic’ MR, 20% have a sub-maximal 
functional capacity on cardiopulmonary exercise testing 
(26). Event-free survival is lower in those asymptomatic 
patients with severe primary MR who have a reduced 
exercise capacity despite good LV function and normal 
LV dimensions (27). In a large study of 884 consecutive 
patients undergoing exercise stress echocardiography, 
exercise capacity (lower than 100% age/sex predicted 
metabolic equivalents (METs) achieved), heart rate 
recovery (HRR, <18 beats within 1 min after exercise) after 
stress- and exercise-induced atrial fibrillation were strong 
independent markers of adverse outcome in primary MR 
(28). These data emphasise the importance of monitoring 
apparently asymptomatic patients using a regular exercise 
test to provide objective assessment of symptom status. 
In those with no exercise limitation according to age- and 
gender-based predicted metabolic equivalents, delay in 
surgery does not impair outcome at one year (29).
If echocardiography is added to the exercise test, 
what further information can be gleaned? First, a change 
in severity of primary MR with exercise is common and 
occurs in over 30% of those with asymptomatic moderate-
to-severe MR (Fig. 1A and B) (30). From a small study of 
61 asymptomatic patients, those who have an increase 
in effective regurgitant orifice area (EROA) of more than 
10 mm2 during exercise have a lower symptom-free 
survival compared with those with no change. Secondly, 
patients with moderate-to-severe MR who develop 
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pulmonary hypertension above 60 mmHg on exercise are 
at greater risk of symptoms and adverse outcomes (Fig. 2A 
and B) (30, 31). Thirdly, an assessment of LV function 
during stress echocardiography can also be an important 
marker of post-operative outcome. The onset of symptoms 
is not only governed by severity of MR and its effect on 
pulmonary pressure but also on the capacity of the LV to 
respond to volume-loading. Resting LV ejection fraction 
can be a poor marker of myocardial contractility as over a 
third of patients with a ‘normal’ pre-operative EF >60%, 
develop LV dysfunction below 50% after successful mitral 
repair (4). Latent contractile dysfunction can be predicted 
by measuring a systolic tissue velocity (<10.5 cm/s at 
rest) (Video 3 and Fig. 3) (32) and by quantifying global 
longitudinal strain (<−20%) (33). Improved outcomes 
can also be predicted by the LV response to exercise. In 
71 consecutive asymptomatic patients with isolated 
moderate-to-severe primary MR, those in whom the LVEF 
failed to increase by ≥4%, had poorer symptom-free 
survival and worse outcomes after MV surgery (34). 
Similarly, a failure in global longitudinal strain to improve 
by ≥2% with exercise (Videos  4 and 5) appears to be a 
more sensitive marker of latent contractile dysfunction 
when indexing strain to end-systolic volume (35).
Video 3
Example of latent contractile dysfunction with normal 
LVEF but systolic tissue velocity below 10.5 cm/s at rest 
(Fig. 3). View Video 3 at http://movie-usa.glencoesoftware.
com/video/10.1530/ERP-16-0019/video-3.
Video 4
Example of reduction in GLS from rest in a patient with 
mitral regurgitation and LVEF >60%. View Video 4 at 
http://movie-usa.glencoesoftware.com/video/10.1530/
ERP-16-0019/video-4.
Figure 1
Colour M-mode demonstrating worsening MR in 
a patient with normal LVEF. There is an increase 
in PISA from rest (A) to exercise (B) while cycling 
at 75 W.
Figure 2
Continuous wave Doppler demonstrating an 
increase in severity of tricuspid regurgitation and 
increase in maximal velocity from rest (A) to 
exercise (B) while cycling at 75 W.
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Video 5
Example of reduction in GLS to exercise in a patient with 
mitral regurgitation and LVEF >60%. View Video 5 at 
http://movie-usa.glencoesoftware.com/video/10.1530/
ERP-16-0019/video-5.
Why does primary MR worsen  
during exercise?
It has been suggested that exercise promotes an increase 
in systolic blood pressure, but pressure increase alone 
should not have a major impact on regurgitation without 
increase in regurgitant orifice as well as flow varies only 
with the square root of the pressure change between 
the LV and atrium (30). It is more likely that this may 
be due to changes in LV and annular geometry (36). 
Exercise-associated reduction in end-systolic volume 
could redefine the relationship between the papillary 
muscles and the zone of apposition of the leaflets (37). 
A further possibility is that the repetitive prolapse of 
a degenerate MV leads to papillary muscle traction, 
resulting in the fibrosis that has been documented on late 
enhancement with cardiovascular magnetic resonance 
imaging (Fig.  4) (38). Fibrosis in turn could promote a 
failure of the papillary muscles to respond to exercise, 
resulting in additional MR, a possibility suggested by 
differences in papillary muscle velocity and excursion in 
those with prolapse (39). These factors require further 
investigation as an understanding of the mechanisms 
of exercise-related MR may in turn further define those 
valves that need early repair.
Current indicators for stress 
echocardiography in primary MR
Current US guidelines support the use of exercise testing 
in the assessment of patients with asymptomatic severe 
valvular heart disease to help identify those with latent 
symptoms and to clarify prognosis (40). European 
guidelines support the addition of echocardiography 
to exercise stress testing in experienced hands for the 
assessment of patients whose symptoms or LV dysfunction 
appear disproportionate to the severity of MR at rest (5, 
41). In the future, use of stress may be more widespread 
because it is possible that careful assessment of the 
patient with asymptomatic severe MR with normal cavity 
dimensions and good LV function may define two groups 
of patients – (1) those who have a good prognosis who 
can avoid surgery despite having a repairable valve and 
(2) those who are more likely to progress to symptoms and 
LV dysfunction who need surgery earlier. Unfortunately, 
there are as yet no randomised data that compare the 
outcome of such a strategy.
Secondary MR
Secondary MR is a dynamic condition where the degree of 
MR at rest does not predict the degree of MR on exertion. 
In a study of 70 consecutive patients with ischaemic LV 
dysfunction, MR decreased in 13 (19%), increased by less 
than 13 mm2 when measured by effective regurgitant 
orifice area (EROA) in 38 (54%) and increased more 
than this in the remaining 19 patients (42). The primary 
determinants of exercise-related deterioration in MR 
appear to be systolic annular area, degree of tenting of 
the valve and the associated wall motion abnormalities 
(42). These are dependent on the extent of ischaemic 
damage, exercise-induced dyssynchrony and the 
presence or absence of viability within the myocardium 
and papillary muscles; indeed, the severity of MR may 
reduce in patients with viable myocardium due to 
myocardial recruitment (43, 44, 45). Whether secondary 
MR improves or deteriorates on exercise is important 
as an increase in severity of MR with exercise by EROA 
≥13 mm2 is associated with a five-fold increased risk of 
subsequent cardiac death (46). These and other data have 
led to support for the role of stress echocardiography in 
Figure 3
Example of latent contractile dysfunction with normal LVEF (Video 3), but 
systolic tissue velocity below 10.5 cm/s at rest.
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the investigation of patients with shortness of breath on 
exertion but who have less than severe secondary MR at 
rest. As yet, however, the role of stress echocardiography 
in the timing of mitral valve surgery in secondary MR 
remains controversial. In part, this is due to the lack 
of data, but in addition, it is not yet clear how best to 
manage patients with secondary MR.
Timing of surgery in chronic secondary MR
Secondary (ischaemic) MR is usually defined as the 
presence of MR either at rest or on exertion present more 
than 2  weeks after myocardial infarction. Although the 
frequency with which MR is detected may vary according 
to the method of imaging and the time at which this is 
carried out after MI, the presence of secondary MR confers 
a graded inverse relationship with risk of cardiovascular 
deaths (RR 1.88, 95% CI 1.23–2.86). Even those with mild 
ischaemic MR have a significantly worse survival (47). 
Although either the presence of MR and/or deterioration 
after exercise identifies a group of patients at particularly 
high risk, there continues to be controversy over whether 
surgical correction improves either life expectancy or 
quality of life (48). MV repair plus CABG was found to 
improve NYHA class, oxygen consumption on exercise 
testing and end-systolic volume index compared with 
CABG alone in a multi-centre study randomising 73 
moderate MR patients, although mortality rates were 
similar in both groups (49). A similar finding was noted 
in a trial of 102 patients with an improvement in 
NYHA class after combined CABG and MV repair (50). 
In contrast, a further randomised study of 301 patients 
did not demonstrate concomitant MV repair led to any 
improvements in LV remodelling at 2-year follow-up but 
instead was associated with longer bypass time, hospital 
stay and more neurological events (48, 51). There is also 
controversy over whether MV repair or MV replacement 
produces the better outcome, with no apparent difference 
in end-systolic volume or mortality between approaches 
but less recurrent MR with replacement (52). These studies 
have generated a debate on whether secondary MR is only 
a marker of poor LV function rather than independently 
contributing to adverse outcome (53). Despite the 
inconsistency of evidence, it remains a class 2A indication 
to include MV repair at the time of CABG if MR is severe, 
whereas repair or replacement may be considered only if 
patients are severely symptomatic despite optimal medical 
therapy (class 2B) (40).
Stress echocardiography in secondary MR?
Although secondary MR may vary during exercise and 
diagnosis is associated with outcome, the question arises 
as to whether stress echocardiography could play a role 
in clarifying treatment strategy in symptomatic patients. 
In clinical practice, the main potential appears to 
be in two groups of patients. First, there are those whose 
symptoms of breathlessness appear to be disproportionate 
to the extent of LV impairment or the severity of MR. 
Exercise echocardiography can be used both to confirm 
objectively the extent of physical limitation (54), 
together with an imaging strategy that can define the 
extent of resting LV impairment, presence of ischaemia, 
development of dyssynchrony and alteration in the 
degree of MR during stress (5, 40, 42, 43). Secondly, the 
degree of secondary MR that is considered significant 
is relatively minor (EROA ≤13 mm2). In those in whom 
there is discussion as to whether percutaneous or surgical 
revascularisation should occur, demonstration of a 
significant exercise-related change in severity of MR or 
pulmonary hypertension would perhaps support surgery 
in those with symptoms (55). The limitation once again 
is that this diagnostic and intervention strategy is based 
on single-centre, non-randomised studies and large 
scale, randomised data are needed.
Figure 4
Late gadolinium enhancement of papillary muscle 
on cardiac MRI (A) and the corresponding cine 
short axis slice (B) in a patient with primary 
degenerative MR and normal LVEF.
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Performing stress echocardiography  
in mitral regurgitation
Stress echocardiography in MR should be preceded 
by a full transthoracic echocardiogram. This baseline 
echocardiogram should include an assessment of 
LV volumes and function, wall motion, aortic root, 
assessment of right ventricular dimensions and function, 
pulmonary pressure and assessment of all valves.
Most published studies have used upright or semi-
supine bicycle exercise as the stressor because this permits 
continuous imaging at all stages of exercise. MR tends to 
Table 1 Standard exercise echocardiography parameters for MR assessment, with key prognostic cut-off values for primary and 
secondary MR.
Parameters
Key prognostic cut-off values in  
primary MR
Key prognostic cut-off values 
in secondary MR
Resting quantitative 
assessment of disease 
severity
Resting BP and HR
EROA
Regurgitant volume
Resting TR maximal velocity and 
calculation for PASP
LA volume
Prospective 456 patients: highest 
survival with EROA <20 mm2. EROA 
>40 mm2 increases 5-year mortality 
rate (risk ratio 2.9) (57).
Prospective 456 patients: adjusted 
mortality risk ratio increases by 1.15 
per 10 mL increase in regurgitant 
volume (57).
Prospective 437 patients: resting PASP 
>50 mmHg is predictor of 
cardiovascular death (HR 2.21) (58).
Prospective 492 patients: LA volume 
>60 mL/m2 reduces survival (HR 1.3), 
reversible with surgery (59).
Prospective 303 patients: MR 
confers a graded inverse 
relationship with cardiac 
mortality (RR 1.88) (47).
Resting left ventricular 
assessment
LV internal dimensions/volumes
Left ventricular ejection fraction
Wall motion score
Inferoseptal and anterolateral s′ 
and e′ tissue velocity
Global longitudinal strain
Class I indications for surgery: LVESD 
≥45 mm in ESC or LVESD ≥40 mm in 
AHA/ACC guidelines (5, 40).
Observational 884 patients: LVEF 
<55% predicted mortality (28).
Retrospective 84 patients: resting 
systolic tissue velocity <10.5 cm/s 
predicts post-op reduction in  
EF (32).
Prospective 135 patients: resting  
GLS >−20% lowers event-free 
survival (33).
Exercise parameters Exercise BP and HR
Heart rate recovery post-exercise
Duration and extent of exercise
Symptoms on exercise
Quantitative MR severity
Peak TR maximal velocity and 
calculation for PASP
Peak LVEF
LVEF
Global longitudinal strain
Observational 884 patients: HRR 
<18 bpm/min predicts adverse 
events (28).
Observational 884 patients: <100% 
predicted METs predicts adverse 
events (28).
Prospective 61 patients: EROA increase 
of >10 mm2 or regurgitant volume 
>15 mL predicts symptom onset (30).
Prospective 102 patients: exercise 
induced PASP >60 mmHg increased 
risk of post-op events (31).
Prospective 71 patients: LVEF fail to 
improve by ≥4% have poorer 
prognosis (34).
Prospective 71 patients: GLS fail to 
improve by ≥1.9% predicts post-op 
EF reduction (35).
Prospective 98 patients: EROA 
during exercise ≥13 mm2 
associated with increased 
cardiac mortality (60).
Prospective 159 patients: 
exercise induced PASP 
>60 mmHg increased rate of 
cardiac events (HR 5.9) (55).
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resolve rapidly with rest, so that although treadmill exercise 
is useful for assessing symptoms and ischaemia, it is less 
so for quantifying change in MR. Moreover, bicycle stress 
provides more isometric stress than aerobic exercise, which 
may be more useful in evaluating MR. Usually, patients 
are asked to maintain a cadence of around 60/min with 
increments in workload of 25 W made at 2-min intervals, 
although protocols can be altered to younger patients 
using higher load (56). Data to be acquired are listed in 
Table  1 with a standard MR exercise echocardiography 
protocol shown in Fig. 5, illustrating the typical sequence 
of data acquisition. This generic protocol can of course 
be modified if there is a specific clinical question – such 
as more emphasis on LV function if there is an interest 
in LV viability. It is also useful to be aware of some of 
the limitations of quantitative echocardiography in MR, 
specifically the proximal isovelocity surface area (PISA) 
method for calculation of effective regurgitant orifice. First, 
the configuration or shape of PISA changes as the aliasing 
velocity changes – the convergence zone is flatter with 
higher aliasing velocities and becomes more elliptical with 
lower aliasing velocities. Secondly, the regurgitant orifice 
may vary during the cardiac cycle, occurring for example 
in the latter half of systole in MV prolapse. Colour M-mode 
can be used to assess variation during the cardiac cycle, but 
this is often not practical during stress. Thirdly, the PISA 
method for quantification of MR is based on the assumption 
that the MR jet is hemispheric proximal to the jet lesion, 
but this is not always the case. This is of greatest practical 
importance in secondary MR, when the PISA orifice may 
become less hemispheric and more ellipsoid, which leads 
to underestimation of severity. There are limited data 
regarding the use of pharmacological stress in MR.
Stress echocardiography in the assessment of 
patients with mitral valve disease is one of the most 
technically demanding skills. It is expected that image 
acquisition requires complete training in transthoracic 
echocardiography, with accreditation through the British 
Society of Echocardiography or the reciprocal European 
Association of Cardiovascular Imaging credentialing. 
Furthermore, the individual should then have a period of 
supervised experience in stress echocardiography, with US 
recommendations for accumulation of 100 cases under 
supervision. The British Society of Echocardiography 
has introduced the first formal accreditation process in 
stress echocardiography that involves a written exam, 
acquisition of 5 cases on video for submission and a 
logbook of 200 cases acquired within 2 years. Candidates 
will also be examined while acquiring images during 
exercise stress. Image interpretation likewise requires 
extensive experience in echocardiography and those 
involved should have specific training.
Summary
Although guidelines for timing of intervention in both 
primary and secondary MR have been established for 
several years, there continues to be controversy as to 
the appropriate timing of surgery. Quantitative exercise 
stress echocardiography may be a useful adjunct to 
the management of patients with both conditions: in 
primary MR, testing helps to select those asymptomatic 
patients with repairable valves to undergo early surgery 
while supporting those patients who may choose to 
delay intervention. In secondary MR, the role of stress 
echocardiography is more controversial but can help 
to identify the mechanism of regurgitation and target 
therapy in disproportionately symptomatic patients.
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